Horizon, Univ. of Liverpool to Collaborate on Cancer Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery today said that it has inked a research collaboration with the University of Liverpool to use the firm's tools to identify and validate cancer drug targets and biomarkers for personalized cancer therapy and diagnostics.

The partners will utilize Horizon's X-Man cell lines and have access to the firm's panel of over 150 genetically-defined isogenic disease models, said Horizon. The company will work with Michael Clague of the University of Liverpool to identify unique protein biomarker signatures.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.